These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12192066)

  • 21. Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex.
    Arasappan A; Njoroge FG; Parekh TN; Yang X; Pichardo J; Butkiewicz N; Prongay A; Yao N; Girijavallabhan V
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5751-5. PubMed ID: 15501035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Product inhibition of the hepatitis C virus NS3 protease.
    Steinkühler C; Biasiol G; Brunetti M; Urbani A; Koch U; Cortese R; Pessi A; De Francesco R
    Biochemistry; 1998 Jun; 37(25):8899-905. PubMed ID: 9636031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus.
    Frecer V; Kabelác M; De Nardi P; Pricl S; Miertus S
    J Mol Graph Model; 2004 Jan; 22(3):209-20. PubMed ID: 14629979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products.
    Ingallinella P; Altamura S; Bianchi E; Taliani M; Ingenito R; Cortese R; De Francesco R; Steinkühler C; Pessi A
    Biochemistry; 1998 Jun; 37(25):8906-14. PubMed ID: 9636032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
    J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides: identification of sequence and critical residues of NS4A for the cofactor activity.
    Butkiewicz NJ; Wendel M; Zhang R; Jubin R; Pichardo J; Smith EB; Hart AM; Ingram R; Durkin J; Mui PW; Murray MG; Ramanathan L; Dasmahapatra B
    Virology; 1996 Nov; 225(2):328-38. PubMed ID: 8918919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites.
    Chanprapaph S; Saparpakorn P; Sangma C; Niyomrattanakit P; Hannongbua S; Angsuthanasombat C; Katzenmeier G
    Biochem Biophys Res Commun; 2005 May; 330(4):1237-46. PubMed ID: 15823576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
    Thibeault D; Massariol MJ; Zhao S; Welchner E; Goudreau N; Gingras R; Llinàs-Brunet M; White PW
    Biochemistry; 2009 Feb; 48(4):744-53. PubMed ID: 19119853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibiting viral proteases: challenges and opportunities.
    Bianchi E; Pessi A
    Biopolymers; 2002; 66(2):101-14. PubMed ID: 12325160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency.
    Arasappan A; Njoroge FG; Chan TY; Bennett F; Bogen SL; Chen K; Gu H; Hong L; Jao E; Liu YT; Lovey RG; Parekh T; Pike RE; Pinto P; Santhanam B; Venkatraman S; Vaccaro H; Wang H; Yang X; Zhu Z; Mckittrick B; Saksena AK; Girijavallabhan V; Pichardo J; Butkiewicz N; Ingram R; Malcolm B; Prongay A; Yao N; Marten B; Madison V; Kemp S; Levy O; Lim-Wilby M; Tamura S; Ganguly AK
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4180-4. PubMed ID: 16087332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation and characterization of proteolytically active and highly stable truncated and full-length recombinant West Nile virus NS3.
    Chappell KJ; Stoermer MJ; Fairlie DP; Young PR
    Protein Expr Purif; 2007 May; 53(1):87-96. PubMed ID: 17174105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of non-macrocyclic small molecule inhibitors against the NS3/4A serine protease of hepatitis C virus through in silico screening.
    Chaudhuri R; Lee H; Truong L; Torres J; Patel K; Johnson ME
    J Chem Inf Model; 2012 Aug; 52(8):2245-56. PubMed ID: 22697413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
    Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
    Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular modeling based approach, synthesis and in vitro assay to new indole inhibitors of hepatitis C NS3/4A serine protease.
    Ismail NS; Hattori M
    Bioorg Med Chem; 2011 Jan; 19(1):374-83. PubMed ID: 21138791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Detection of proteolytic activity of hepatitis C virus NS3-4A protease using enzymelinked immunosorbent assay].
    Chen X; Guo J; Chen H; Wanglin
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Jun; 22(3):300-2. PubMed ID: 12903484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity.
    Hahm B; Back SH; Lee TG; Wimmer E; Jang SK
    Virology; 1996 Dec; 226(2):318-26. PubMed ID: 8955051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptidic inhibitors of the hepatitis C virus serine protease within non-structural protein 3.
    Fischmann TO; Weber PC
    Curr Pharm Des; 2002; 8(28):2533-40. PubMed ID: 12369938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design.
    Murthy HM; Judge K; DeLucas L; Padmanabhan R
    J Mol Biol; 2000 Aug; 301(4):759-67. PubMed ID: 10966782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The RNA aptamer-binding site of hepatitis C virus NS3 protease.
    Hwang J; Fauzi H; Fukuda K; Sekiya S; Kakiuchi N; Shimotohno K; Taira K; Kusakabe I; Nishikawa S
    Biochem Biophys Res Commun; 2000 Dec; 279(2):557-62. PubMed ID: 11118325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.